ReviewBrain research2020
Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.
Review in Brain research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Small molecule orexin agonist ROXA-47 enhances learning and memory in mice.Pharmacology, biochemistry, and behavior · 2026Article
- Sex differences in interactions between the muscarinic-1 and orexin-1 receptors on cognitive flexibility in rats.Brain research · 2026Article
- Orexinergic modulation of chronic jet lag-induced deficits in mouse cognitive flexibility.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Hypocretin: a promising target for the regulation of homeostasis.Frontiers in neuroscience · 2025Review
- Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders.Frontiers in medicine · 2024Review
- The potential role of the orexin system in premenstrual syndrome.Frontiers in endocrinology · 2023Review
- Novel Design of Neuropeptide-Based Drugs with β-Sheet Breaking Potential in Amyloid-Beta Cascade: Molecular and Structural Deciphers.International journal of molecular sciences · 2022Article
- Associations Between Self-Reported Sleep Disturbances and Cognitive Impairment: A Population-Based Cross-Sectional Study.Nature and science of sleep · 2022Article
- Orexin (hypocretin) mediates light-dependent fluctuation of hippocampal function in a diurnal rodent.Hippocampus · 2021Article
- Intranasal insulin and orexins to treat age-related cognitive decline.Physiology & behavior · 2021Review
- Intranasal Orexin After Cardiac Arrest Leads to Increased Electroencephalographic Gamma Activity and Enhanced Neurologic Recovery in Rats.Critical care explorations · 2021Article
- Orexin and Alzheimer's Disease: A New Perspective.Psychiatry investigation · 2020Article
- The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task.Brain research · 2020Article
- Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"Brain research · 2020Article
- Reduced Plasma Orexin-A Concentrations are Associated with Cognitive Deficits in Anorexia Nervosa.Scientific reports · 2019Observational
- Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats.Frontiers in aging neuroscience · 2019Article
- Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review.Brain circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cognitive impairment is a core feature of several neuropsychiatric and neurological disorders, including narcolepsy and age-related dementias. Current pharmacotherapeutic approaches to cognitive enhancement are few in number and limited in efficacy. Thus, novel treatment strategies are needed. The hypothalamic orexin (hypocretin) system, a central integrator of physiological function, plays an important role in modulating cognition. Several single- and dual-orexin receptor antagonists are available for various clinical and preclinical applications, but the paucity of orexin agonists has limited the ability to research their therapeutic potential. To circumvent this hurdle, direct intranasal administration of orexin peptides is being investigated as a prospective treatment for cognitive dysfunction, narcolepsy or other disorders in which deficient orexin signaling has been implicated. Here, we describe the possible mechanisms and therapeutic potential of intranasal orexin delivery. Combined with the behavioral evidence that intranasal orexin-A administration improves cognitive function in narcoleptic and sleep-deprived subjects, our neurochemical studies in young and aged animals highlights the capacity for intranasal orexin administration to improve age-related deficits in neurotransmission. In summary, we highlight prior and original work from our lab and from others that provides a framework for the use of intranasal orexin peptides in treating cognitive dysfunction, especially as it relates to age-related cognitive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.